Dr Katy Bell

Katy Bell photoMBChB, MMed (Clin. Epi), PhD

katy.bell@sydney.edu.au;

cbell@bond.edu.au
Assistant Professor, CREBP
Faculty of Health Sciences and Medicine
Bond University

Research Academic Affiliate, Screening & Test Evaluation Program (STEP), School of Public Health, University of Sydney

 

Research Interests

Katy is especially interested in methodological research into the evaluation of screening, diagnostic and monitoring tests. Much of her recent research has looked at ways clinicians may monitor chronic disease, both before and after starting treatment. Examples of chronic diseases examined so far and under current study include: cardiovascular disease, osteoporosis, rheumatoid arthritis, melanoma and prostate cancer.

Qualifications


Doctor of Philosophy – University of Sydney

Masters of Medicine (Clinical Epidemiology) – University of Sydney

Basic Sciences Examinaton – Royal College of Pathologists of Australasia

Bachelor of Medicine Bachelor of Surgery – University of Otago

Membership of Scientific Societies

Australasian Epidemiological Association

Current research grants

NHMRC Early Career Fellowship

Bond University Faculty of Medicine and Health Sciences Seeding Grant

Teaching Experience

Katy has helped teach evidence-based medicine to medical practitioners undertaking the Masters of Medicine (Clinical Epidemiology) at the University of Sydney since 2006.

Publications:

  1. Hayen A, Bell K, Glasziou P, Irwig I. A counterargument to Encounter Frequency and Target Achievement: Measurement Variability. Arch Intern Med. 2012;172:374
  2. Turner RM, Bell KJL, Morton RL, Hayen, A, Francken AB, Howard K, Armstrong B, Thompson JF, Irwig L. Optimizing the Frequency of Follow-Up Visits for Patients Treated for Localized Primary Cutaneous Melanoma. JCO Published online Nov 7 2011
  3. Bell KJL, Hayen A, Irwig L, Hochberg MC, Ensrud KE, Cummings S, Bauer DC. The potential value of monitoring bone turnover markers among women on alendronate. Journal of Bone and Mineral Research. Published online October 2011. DOI: 10.1002/jbmr.525
  4. Bell KJL, Hayen A, McGeechan K, Neal BC and Irwig L. Effects of additional blood pressure and lipid measurements on the prediction of cardiovascular risk. European Journal of Cardiovascular Prevention and Rehabilitation. Published online Sept 26 2011
  5. Bell, K, Kirby, A, Hayen, A, Irwig, L, Glasziou, P. Monitoring adherence to drug treatment by using change in cholesterol concentration: secondary analysis of trial data. BMJ. 2011; 342:d12
  6. Hayen A, Bell K, Glasziou P, Neal BC, Irwig L. Monitoring Adherence to Medication by Measuring Change in Blood Pressure. Hypertension. Published online Aug 9, 2010
  7. Bell KJL, Hayen A, Macaskill P, Craig JC, Neal BC, Fox KM, Remme WJ, Asselbergs FW, van Gilst WH, MacMahon S, G. R, P. R, Teo KK and Irwig L. Monitoring initial response to angiotensin converting enzyme inhibitor based regimens: an individual patient data meta-analysis from randomised placebo controlled trials. Hypertension. 2010;56:533-9
  8. Bell K, Irwig L, March L, Hayen A, Macaskill P, Craig JC.  Should response rules be used to decide continued subsidy of very expensive drugs? A checklist for decision makers.  Pharmacoepidemiology and Drug Safety 2010; 19(1):99-105
  9. Bell KJL, Hayen A, Macaskill P, Irwig L, Craig JC, Ensrud KEE and Bauer DC. Letter to the Editor: The Value of Routine BMD Monitoring After Starting Bisphosphonate Treatment. Journal of Bone and Mineral Research 2009; doi:10.1359/jbmr.091111
  10. Bell KJL, Hayen A, Macaskill P, Irwig L, Craig JC, Ensrud KEE and Bauer DC. Value of routine monitoring of bone mineral density after starting bisphosphonate treatment: secondary analysis of trial data. BMJ 2009;338:b2266
  11. Bell KJL, Hayen A, Macaskill P, Craig JC, Neal BC and Irwig L. Mixed models showed no need for initial response monitoring after starting anti-hypertensive therapy Journal of Clinical Epidemiology 2009;62:650-9
  12. Gupta S, Wratten C, Kilmurray J, Nash S, Seldon M, O’Brien PC, Bell KJL, Denham JW. Is there a relationship between skin erythema and fatigue in women undergoing irradiation after breast conserving surgery for early breast cancer? : A prospective study. Asia–Pacific Journal of Clinical Oncology 2009;5:257–263
  13. Lincz L, Gupta S, Wratten C, Kilmurray J, Nash S, Seldon M, O’Brien P, Bell K, Denham J. Thrombin generation as a predictor of radiotherapy induced skin erythema. Radiotherapy and Oncology 2009;90(1):136-140
  14. Bell KJL, Irwig L, Craig JC and Macaskill P. Use of randomized trials to decide when to monitor response to new treatment. BMJ. 2008; 336: 361-365
  15. BellK,Wattie M, Byth K, Silvestrini R, Clark P, Stachowski E and Benson EM. Procalcitonin: a marker of bacteraemia in SIRS.Anaesthesia & Intensive Care.2003; 31(6):629-36
  16. Bell KJL, Craig JC, Irwig L. Chapter 6, ‘Monitoring the initial response to treatment’ in Evidence-Based Medical Monitoring: from Principles to Practice, Glasziou P, Aronson J, Irwig L (eds). Page 75-89. Massachusetts: Blackwell Publishing, 2008

 

Conference and Seminar presentations:

  1. Bell KJL, Hayen A, Irwig L, Glasziou P. Monitoring absolute cardiovascular risk: how often do we need to re-measure? School of Public Health and Community Medicine Lunchtime Seminar, University of New South Wales, Sydney, Australia 2012
  2. Bell KJL, Hayen A, Irwig L, Glasziou P. Monitoring absolute cardiovascular risk: how often do we need to re-measure?School of Public Health Seminar Presented by the Screening & Test Evaluation Program (STEP), University of Sydney, Sydney, Australia 2012
  3. Bell KJL, Hayen A, McGeechan K, Neal BC and Irwig L. Effects of additional blood pressure and lipid measurements on the prediction of cardiovascular risk. AEA Scientific Meeting, Perth, Australia 2011
  4. Bell KJL, Hayen A, Macaskill P, Craig JC, Neal BC, Irwig L. Do we need to monitor initial response? Blood pressure monitoring in the PROGRESS trial. School of Public Health Seminar Presented by the Screening & Test Evaluation Program (STEP), University of Sydney, Australia 2008
  5. Bell KJL, Hayen A, Macaskill P, Craig JC, Neal BC, Irwig L. Do we need to monitor initial response? Blood pressure monitoring in the PROGRESS trial. 2008 Population Health Congress, Brisbane, Australia 2008
  6. Bell KJL, Craig J. and Irwig L. Using summary data from randomised trials to decide when to monitor response to new treatment. 2007 Joint Scientific Meetings of AEA/IEA-Western Pacific Region, Hobart, Australia 2007
  7. Bell K, Craig J and Irwig L. Is there an initial response? Evidence Based Practice conference (for book chapter authors), Budapest, Hungary 2006